Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Zacopride. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.88 |
| ▸ | KMT2A known ✓ | Q03164 | 1/20 | 0.88 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.56 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.56 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.56 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.56 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.56 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.56 |
| ▸ | HTR3A | P46098 | 4/20 | 0.88 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.88 |
| ▸ | HTR3B | O95264 | 2/20 | 0.88 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.88 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.88 |
| ▸ | HTR5A | P47898 | 1/20 | 0.88 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.88 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.88 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.88 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.85 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zacopride SCHEMBL7288008 | 1.00 | HTR3A (0.88) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Zacopride SCHEMBL7200880 | 1.00 | HTR3A (0.88) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Zacopride SCHEMBL29567897 | 0.94 | HTR3A (1.00) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Zacopride SCHEMBL5373467 | 0.94 | HTR3A (1.00) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Zacopride SCHEMBL16003 | 0.94 | HTR3A (1.00) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| (R)Zacopride SCHEMBL5387843 | 0.94 | HTR3A (1.00) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Zacopride SCHEMBL7280994 | 0.93 | MAPK1 (0.98) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Zacopride SCHEMBL7280998 | 0.93 | MAPK1 (0.98) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Zacopride SCHEMBL667580 | 0.93 | MAPK1 (0.98) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Zacopride SCHEMBL7281576 | 0.93 | MAPK1 (0.98) | HTR3AHTR3EHTR3BHTR3DHTR3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0190920-B1 | METHOD OF ENHANCING MEMORY OR CORRECTING MEMORY DEFICIENCY WITH ARYLAMIDO (AND ARYLTHIOAMIDO)AZABICYCLOALKANES | SYNTHELABO (FR) | 1993-05-05 | — | — | EP | disclosed |
| US-5206246-A | Anxiolytic agents | A. H. ROBINS COMPANY, INCORPORATED (US) | 1993-04-27 | — | — | US | disclosed |
| EP-0306345-B1 | 2-ALKOXY-N-(1-AZABICYCLO(2.2.2)-OCT-3-YL) BENZAMIDES AND THIOBENZAMIDES HAVING AN ANTISCHIZOPHRENIC ACTIVITY | SYNTHELABO (FR) | 1993-04-14 | — | — | EP | disclosed |
| EP-0353372-B1 | Antischizophrenic-S-N-(1-azabicyclo[2.2.2.]oct-3-yl) benzamides and thiobenzamides | SYNTHELABO (FR) | 1993-02-03 | — | — | EP | disclosed |
| EP-0190915-B1 | Process for the preparation of 2-alkoxy-N-(1-azabicyclo[2.2.2]octan-3-yl) aminobenzamides | SYNTHELABO (FR) | 1992-10-28 | — | — | EP | disclosed |
| EP-0327335-B1 | ARYLAMIDO(AND ARYLTHIOAMIDO)-AZABICYCLOALKANES FOR ENHANCING MEMORY OR CORRECTING MEMORY DEFICIENCY | SYNTHELABO (FR) | 1992-10-14 | — | — | EP | disclosed |
| EP-0272052-B1 | Anxiolytic-N-(1-Azabicyclo[2.2.2]Oct-3-yl) Benzamides and Thobenzamides | A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) (US) | 1992-07-08 | — | — | EP | disclosed |
| US-5025022-A | Method of treating or preventing schizophrenia and/or psychosis using S-N-(1-azabicyclo[2.2.2]oct-3-yl)benzamides and thiobenzamides | A.H. ROBINS COMPANY, INCORPORATED A VA CORPORATION | 1991-06-18 | — | — | US | disclosed |
| US-5017580-A | Memory enhancing-R-N-(1-azabicyclo[2.2.2.]oct-3-yl)benzamides and thiobenzamides | A.H. ROBINS COMPANY, INCORPORATED A VA CORPORATION | 1991-05-21 | — | — | US | disclosed |
| US-4908370-A | Antianxiety agents | A. H. ROBBINS COMPANY, INC. (US) | 1990-03-13 | — | — | US | disclosed |
| EP-0272052-A1 | Anxiolytic-N-(1-Azabicyclo[2.2.2]Oct-3-yl) Benzamides and Thobenzamides | A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) (US) | 1988-06-22 | — | — | EP | disclosed |
| US-4722834-A | Method of using 2-alkoxy-N-(1-azabicyclo[2.2.2]oct-3-yl)benzamide-N-oxides to control emesis caused by anticancer drugs | A. H. ROBINS COMPANY, INCORPORATED (US) | 1988-02-02 | — | — | US | disclosed |
| US-4717563-A | 2-alkoxy-N-(1-azabicyclo(2.2.2)oct-3-yl) benzamides and thiobenzamides in a method for alleviating emesis caused by non-platinum anticancer drugs | A. H. ROBINS COMPANY, INC. (US) | 1988-01-05 | — | — | US | disclosed |
| EP-0240180-A1 | 2-alkoxy-N-(1-azabicyclo[2.2.2]-oct-3-yl) benzamides and thiobenzamides in the alleviation of emesis caused by non-platinum anticancer drugs | SYNTHELABO (FR) | 1987-10-07 | — | — | EP | disclosed |
| EP-0237281-A1 | 2-alkoxy-N-(1-azabicyclo[2.2.2]-oct-3-yl) benzamide-N-oxides in the control of emesis caused by anticancer drugs | SYNTHELABO (FR) | 1987-09-16 | — | — | EP | disclosed |
| EP-0190915-A2 | Process for the preparation of 2-alkoxy-N-(1-azabicyclo[2.2.2]octan-3-yl) aminobenzamides | SYNTHELABO (FR) | 1986-08-13 | — | — | EP | disclosed |
| EP-0190920-A2 | Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)azabicycloalkanes | SYNTHELABO (FR) | 1986-08-13 | — | — | EP | disclosed |
| US-4605652-A | ALZHEIMER'S DISEASE; SENILITY | A. H. ROBINS COMPANY, INC. (US) | 1986-08-12 | — | — | US | disclosed |
| US-4593034-A | 2-alkoxy-N-(1-azabicyclo[2.2.2]oct-3-yl)benzamides and thiobenzamides | A. H. ROBINS COMPANY, INC. (US) | 1986-06-03 | — | — | US | disclosed |
| EP-0158532-A2 | Use of 4-amino-N-(1-azabicyclo[2.2.2]oct-3-yl)-5-chloro-2-methoxybenzamide for the manufacture of a medicament having anti-emetic activity. | SYNTHELABO (FR) | 1985-10-16 | — | — | EP | disclosed |